Business
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
- New crystal structure data supporting SNS-101 mechanism of action - BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE),
About this update from Sensei Biotherapeutics, Inc.
[{"type":"text","content":"- New crystal structure data supporting SNS-101 mechanism of action -\nBOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia. “Preclinical studies to date have demonstrated SNS-101’s potential to significantly enhance the anti-tumor effects of PD-1 blockade while abrogating target-mediated drug disposition (TMDD) and with lower risk of cytokine release syndrome (CRS). New crystal structure analysis further elucidates the antibody’s mechanism of action, showing that SNS-101 directly blocks the pH-dependent interaction between VISTA and PSGL-1,” said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics. “Together, these preclinical data support the biological rationale for our pH-dependent approach, which we believe is key to targeting active protonated VISTA with exquisite selectivity.” Presentation highlights: The epitope of SNS-101 was determined by co-crystallization of VISTA with the fragment antigen-binding domain of SNS-101. Crystal structure analysis suggests SNS-101 directly blocks the pH-dependent interaction between VISTA and PSGL-1, as well as interactions with other putative receptors.In vitro and in vivo assays demonstrated that treatment with SNS-101 potentially has a significantly lower risk of inducing CRS than a non-pH-dependent VISTA antibody.SNS-101 exhibited linear elimination kinetics in non-human primates, overcoming TMDD-induced pharmacokinetic limitations observed with other anti-VISTA antibodies.SNS-101 induced expansion of naïve and memory T-cell phenotypes in vivo without activation or depletion of monocytes, differentiating it from non-pH-selective antibodies.SNS-101 demonstrated significant enhancement of anti-tumor effects in combination with anti-PD-1 antibodies in syngeneic tumor models. Sensei expects to submit an Investigational New Drug (IND) application for SNS-101 in or before April 2023, with a Phase 1/2 clinical trial expected to commence in 2023, pending regulatory clearance. A poster summari...